AbbVie Posts Upbeat Q2 Earnings, But Sales Miss Expectations

Loading...
Loading...
Shares of
AbbVie Inc
ABBV
declined more than 2 percent in pre-market trading after the company reported downbeat sales for the second quarter. However, the company's profit exceeded analysts' estimates. The North Chicago, Illinois-based company reported a quarterly net profit of $1.37 billion, or $0.83 per share, compared to $1.1 billion, or $0.68 per share, in the year-ago quarter. Excluding non-recurring items, the company's adjusted earnings came in at $1.08 per share. Its revenue climbed 11.1 percent to $5.48 billion, while sales an operational basis surged 19.4 percent. Analysts were expecting earnings of $1.06 per share on revenue of $5.62 billion. The average estimate among 23 Estimize users was for earnings of $1.06 per share and revenue of $5.59 billion. Its sales of Humira rose 7.6 percent to $3.54 billion. Adjusted operating margin in the second quarter widened to 44.2 percent, from 36.4 percent in the year-ago quarter. Adjusted research and development in the quarter was 15.9 percent of sales. "We are pleased with the high level of performance we've delivered through the first-half of 2015, consistent with our commitment to shareholders for top-tier growth this year and beyond," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "With the completion of the Pharmacyclics transaction, continued momentum from our on-market products and rapid evolution of our robust development pipeline, we are well positioned to deliver strong performance in the future." AbbVie reaffirmed its FY15 adjusted earnings forecast of $4.10 to $4.30 per share, versus analysts' estimates of $4.24 per share. AbbVie shares fell 2.86 percent to $68.50 in pre-market trading.
Loading...
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceprofit
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...